Search This Blog

Wednesday, September 21, 2022

iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline

  Positions Company for leadership in AI-powered drug discovery –

– Expands iBio’s immuno-oncology pipeline with three new candidates –

– Hosting investor call on September 27th to discuss transaction, the Company’s transformation and FY2022 financial results –

The Company will report its fiscal fourth quarter and full year 2022 financial results after market close on Tuesday, September 27, 2022, and will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results, give more information on the RubrYc transaction and strategic review, and provide additional updates. The live and archived webcast may be accessed on the Company’s website at under “News and Events” in the Investors section. To access the live call by phone, participants should go to this registration link, where they will be provided with the dial-in details.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.